Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of G3BP1 and VEZT Expression in Gastric Cancer and Their Possible Correlation with Tumor Clinicopathological Factors

  • Received : 2016.12.01
  • Accepted : 2017.03.04
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to analyze G3BP1 and VEZT expression profiles in patients with gastric cancer, and examine the possible relationship between the expressions of each gene and clinicopathological factors. Materials and Methods: Expression of these genes in formalin-fixed paraffin embedded (FFPE) tissues, collected from 40 patients with gastric cancer and 40 healthy controls, was analyzed. Differences in gene expression among patient and normal samples were identified using the GraphPad Prism 5 software. For the analysis of real-time polymerase chain reaction products, GelQuantNET software was used. Results: Our findings demonstrated that both VEZT and G3BP1 mRNA expression levels were downregulated in gastric cancer samples compared with those in the normal controls. No significant relationship was found between the expression of these genes and gender (P-value, 0.4835 vs. 0.6350), but there were significant changes associated with age (P-value, 0.0004 vs. 0.0001) and stage of disease (P-value, 0.0019 vs. 0.0001). In addition, there was a direct relationship between VEZT gene expression and metastasis (P-value, 0.0462), in contrast to G3BP1 that did not demonstrate any significant correlation (P-value, 0.1833). Conclusions: The results suggest that expression profiling of VEZT and G3BP1 can be used for diagnosis of gastric cancer, and specifically, VEZT gene could be considered as a biomarker for the detection of gastric cancer progression.

Keywords

References

  1. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 2014;11:664-674. https://doi.org/10.1038/nrgastro.2014.143
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. https://doi.org/10.3322/caac.21254
  3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  4. Lagergren J, Andersson G, Talback M, Drefahl S, Bihagen E, Harkonen J, et al. Marital status, education, and income in relation to the risk of esophageal and gastric cancer by histological type and site. Cancer 2016;122:207-212. https://doi.org/10.1002/cncr.29731
  5. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2015;51:1164-1187. https://doi.org/10.1016/j.ejca.2013.09.002
  6. Fu DG. Epigenetic alterations in gastric cancer (Review). Mol Med Rep 2015;12:3223-3230. https://doi.org/10.3892/mmr.2015.3816
  7. Carcas LP. Gastric cancer review. J Carcinog 2014;13:14. https://doi.org/10.4103/1477-3163.146506
  8. Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (Review). Oncol Lett 2015;9:1502-1508. https://doi.org/10.3892/ol.2015.2959
  9. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22. https://doi.org/10.1038/nrc969
  10. Min L, Ruan Y, Shen Z, Jia D, Wang X, Zhao J, et al. Overexpression of Ras-GTPase-activating protein SH3 domain-binding protein 1 correlates with poor prognosis in gastric cancer patients. Histopathology 2015;67:677-688. https://doi.org/10.1111/his.12695
  11. Guitard E, Parker F, Millon R, Abecassis J, Tocque B. G3BP is overexpressed in human tumors and promotes S phase entry. Cancer Lett 2001;162:213-221. https://doi.org/10.1016/S0304-3835(00)00638-8
  12. Taniuchi K, Nishimori I, Hollingsworth MA. The N-terminal domain of G3BP enhances cell motility and invasion by posttranscriptional regulation of BART. Mol Cancer Res 2011;9:856-866. https://doi.org/10.1158/1541-7786.MCR-10-0574
  13. Barnes CJ, Li F, Mandal M, Yang Z, Sahin AA, Kumar R. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res 2002;62:1251-1255.
  14. Winslow S, Leandersson K, Larsson C. Regulation of PMP22 mRNA by G3BP1 affects cell proliferation in breast cancer cells. Mol Cancer 2013;12:156. https://doi.org/10.1186/1476-4598-12-156
  15. Zhang HZ, Liu JG, Wei YP, Wu C, Cao YK, Wang M. Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis. World J Gastroenterol 2007;13:4126-4130. https://doi.org/10.3748/wjg.v13.i30.4126
  16. Parker F, Maurier F, Delumeau I, Duchesne M, Faucher D, Debussche L, et al. A Ras-GTPase-activating protein SH3-domain-binding protein. Mol Cell Biol 1996;16:2561-2569. https://doi.org/10.1128/MCB.16.6.2561
  17. Kennedy D, French J, Guitard E, Ru K, Tocque B, Mattick J. Characterization of G3BPs: tissue specific expression, chromosomal localisation and rasGAP(120) binding studies. J Cell Biochem 2001;84:173-187.
  18. Tourriere H, Chebli K, Zekri L, Courselaud B, Blanchard JM, Bertrand E, et al. The RasGAP-associated endoribonuclease G3BP assembles stress granules. J Cell Biol 2003;160:823-831. https://doi.org/10.1083/jcb.200212128
  19. Gallouzi IE, Parker F, Chebli K, Maurier F, Labourier E, Barlat I, et al. A novel phosphorylation-dependent RNase activity of GAP-SH3 binding protein: a potential link between signal transduction and RNA stability. Mol Cell Biol 1998;18:3956-3965. https://doi.org/10.1128/MCB.18.7.3956
  20. Miao R, Guo X, Zhi Q, Shi Y, Li L, Mao X, et al. VEZT, a novel putative tumor suppressor, suppresses the growth and tumorigenicity of gastric cancer. PLoS One 2013;8:e74409. https://doi.org/10.1371/journal.pone.0074409
  21. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297. https://doi.org/10.1016/S0092-8674(04)00045-5
  22. Li YS, Chen YZ, Guo XB, Liu X, Li LP. VEZT as a novel independent prognostic factor in gastric cancer. Cancer Biomark 2015;15:375-380. https://doi.org/10.3233/CBM-150476
  23. Bahloul A, Simmler MC, Michel V, Leibovici M, Perfettini I, Roux I, et al. Vezatin, an integral membrane protein of adherens junctions, is required for the sound resilience of cochlear hair cells. EMBO Mol Med 2009;1:125-138. https://doi.org/10.1002/emmm.200900015
  24. Guo X, Jing C, Li L, Zhang L, Shi Y, Wang J, et al. Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c. Biochem Biophys Res Commun 2011;404:622-627. https://doi.org/10.1016/j.bbrc.2010.12.026
  25. Ortega AD, Willers IM, Sala S, Cuezva JM. Human G3BP1 interacts with ${\beta}$-F1-ATPase mRNA and inhibits its translation. J Cell Sci 2010;123:2685-2696. https://doi.org/10.1242/jcs.065920
  26. Izadi A, Moslemi E, Poorhosseini SM, Yassaee VR, Kheiri HR, Elikai HR. UBD identify in paraffin tissues in patients with colorectal cancer. J Isfahan Med Sch 2014;32:1-10.
  27. Kim J, Cho YA, Choi WJ, Jeong SH. Gene-diet interactions in gastric cancer risk: a systematic review. World J Gastroenterol 2014;20:9600-9610. https://doi.org/10.3748/wjg.v20.i28.9600
  28. Somasekharan SP, El-Naggar A, Leprivier G, Cheng H, Hajee S, Grunewald TG, et al. YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. J Cell Biol 2015;208:913-929. https://doi.org/10.1083/jcb.201411047
  29. Annibaldi A, Dousse A, Martin S, Tazi J, Widmann C. Revisiting G3BP1 as a RasGAP binding protein: sensitization of tumor cells to chemotherapy by the RasGAP 317-326 sequence does not involve G3BP1. PLoS One 2011;6:e29024. https://doi.org/10.1371/journal.pone.0029024
  30. Kim MM, Wiederschain D, Kennedy D, Hansen E, Yuan ZM. Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP). Oncogene 2007;26:4209-4215. https://doi.org/10.1038/sj.onc.1210212

Cited by

  1. Rasputin a decade on and more promiscuous than ever? A review of G3BPs vol.1866, pp.3, 2017, https://doi.org/10.1016/j.bbamcr.2018.09.001